COMPANY

PEEL Therapeutics

HQ: Salt Lake City, UT source · peeltx.com ↗ · Mountain

Keywords: oncology cancer small molecule pediatric osteosarcoma PEEL-224

Location: Salt Lake City, UT · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Jul 11, 2022 Trial start Phase 1: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors source ↗

2026-10 (ESTIMATED) · Phase 1 · A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors · NCT05329103

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05329103	A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors	Phase 1	Recruiting	Jul 11, 2022	2026-10 (estimated)

Annual award amounts. Total $600K.

Apr 15, 2021 NIH award 1R43AI155239-01A1 FY2021: $299,675 awarded for that fiscal year; activity R43 (SBIR); PI CAULIN, ALEAH FOX; recipient as written: PEEL THERAPEUTICS, INC., Salt Lake City, UT. Selection of a lead candidate f source ↗
Jul 26, 2018 NIH award 1R41CA221653-01A1 FY2018: $300,465 awarded for that fiscal year; activity R41 (STTR); PI SCHIFFMAN, JOSHUA DAVID; recipient as written: PEEL THERAPEUTICS, INC., Salt Lake City, UT. In vitro and in vivo eval source ↗